Manitoba Centre for Proteomics and Systems Biology, Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; Department of Immunology, University of Manitoba, Winnipeg, Canada.
Manitoba Centre for Proteomics and Systems Biology, Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.
Biochim Biophys Acta Mol Basis Dis. 2020 Dec 1;1866(12):165950. doi: 10.1016/j.bbadis.2020.165950. Epub 2020 Aug 22.
IL-33 induces airway inflammation and hyper-responsiveness in respiratory diseases. Although defined as a therapeutic target, there are limited studies that have comprehensively investigated IL-33-mediated responses in the lungs in vivo. In this study, we characterized immunological and physiological responses induced by intranasal IL-33 challenge, in a mouse model. We identified specific cytokines, IL-4, IL-5, IL-6, IL-10, IP-10 and MIP1-α, that are increased in bronchoalveolar lavage and lung tissues by IL-33. Using transcriptomics (RNA-Seq) we demonstrated that 2279 transcripts were up-regulated and 1378 downregulated (≥ 2-fold, p < 0.01) in lung tissues, in response to IL-33. Bioinformatic interrogation of the RNA-Seq data was used to predict biological pathways and upstream regulators involved in IL-33-mediated responses. We showed that the mRNA and protein of STAT4, a predicted upstream regulator of IL-33-induced transcripts, was significantly enhanced in the lungs following IL-33 challenge. Overall, this study provides specific IL-33-induced molecular targets and endpoints that can be used as a resource for in vivo studies, e.g. in preclinical murine models examining novel interventions to target downstream effects of IL-33.
IL-33 在呼吸道疾病中诱导气道炎症和高反应性。尽管被定义为治疗靶点,但很少有研究全面研究过体内 IL-33 介导的肺部反应。在这项研究中,我们在小鼠模型中表征了鼻内 IL-33 挑战引起的免疫和生理反应。我们确定了特定的细胞因子,IL-4、IL-5、IL-6、IL-10、IP-10 和 MIP1-α,这些细胞因子在 IL-33 刺激下在支气管肺泡灌洗液和肺组织中增加。使用转录组学(RNA-Seq),我们证明了 2279 个转录本上调和 1378 个转录本下调(≥ 2 倍,p < 0.01),这是对 IL-33 做出的响应。对 RNA-Seq 数据的生物信息学分析用于预测参与 IL-33 介导的反应的生物学途径和上游调节剂。我们表明,STAT4 的 mRNA 和蛋白质,IL-33 诱导的转录本的预测上游调节剂,在 IL-33 挑战后在肺部显著增强。总体而言,这项研究提供了特定的 IL-33 诱导的分子靶标和终点,可作为体内研究的资源,例如在检查针对 IL-33 下游效应的新型干预措施的临床前小鼠模型中。